Calamos Advisors LLC Buys Shares of 60,694 Axonics, Inc. (NASDAQ:AXNX)

Calamos Advisors LLC purchased a new stake in shares of Axonics, Inc. (NASDAQ:AXNX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 60,694 shares of the company's stock, valued at approximately $3,777,000. Calamos Advisors LLC owned about 0.12% of Axonics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. RiverPark Advisors LLC lifted its position in Axonics by 14.4% in the fourth quarter. RiverPark Advisors LLC now owns 1,185 shares of the company's stock valued at $74,000 after buying an additional 149 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its position in Axonics by 5.9% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 3,120 shares of the company's stock valued at $195,000 after buying an additional 175 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in Axonics by 4.3% in the third quarter. Integrated Wealth Concepts LLC now owns 5,169 shares of the company's stock valued at $290,000 after buying an additional 215 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Axonics by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 19,809 shares of the company's stock valued at $1,000,000 after buying an additional 217 shares during the last quarter. Finally, LPL Financial LLC lifted its position in Axonics by 6.3% in the second quarter. LPL Financial LLC now owns 3,727 shares of the company's stock valued at $211,000 after buying an additional 222 shares during the last quarter. Institutional investors and hedge funds own 99.48% of the company's stock.

Axonics Price Performance

Shares of AXNX stock traded down $0.10 during trading hours on Friday, hitting $66.95. The stock had a trading volume of 594,104 shares, compared to its average volume of 1,014,945. The firm has a market capitalization of $3.41 billion, a PE ratio of -514.96 and a beta of 0.56. Axonics, Inc. has a twelve month low of $47.59 and a twelve month high of $69.68. The stock's 50 day moving average is $68.02 and its 200 day moving average is $62.52.

Axonics (NASDAQ:AXNX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.07. The business had revenue of $109.70 million during the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative return on equity of 1.00% and a negative net margin of 1.66%. The company's revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.01 earnings per share. As a group, equities analysts predict that Axonics, Inc. will post 0.32 earnings per share for the current year.

Insider Activity

In other news, CEO Raymond W. Cohen sold 35,161 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $2,381,806.14. Following the completion of the sale, the chief executive officer now directly owns 188,835 shares of the company's stock, valued at $12,791,682.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Raymond W. Cohen sold 35,161 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $2,381,806.14. Following the completion of the sale, the chief executive officer now directly owns 188,835 shares of the company's stock, valued at $12,791,682.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kari Leigh Keese sold 3,489 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $236,344.86. Following the sale, the chief financial officer now directly owns 43,323 shares of the company's stock, valued at $2,934,700.02. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,837 shares of company stock valued at $4,459,798. 1.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have commented on AXNX. Truist Financial reaffirmed a "hold" rating and issued a $71.00 target price (down previously from $73.00) on shares of Axonics in a research report on Friday, January 12th. Wolfe Research lowered shares of Axonics from an "outperform" rating to a "peer perform" rating in a research note on Tuesday, January 9th. Needham & Company LLC reiterated a "hold" rating on shares of Axonics in a research note on Wednesday, January 17th. Piper Sandler reiterated a "neutral" rating and set a $71.00 price target (down from $75.00) on shares of Axonics in a research note on Friday, January 12th. Finally, SVB Leerink reiterated a "market perform" rating and set a $71.00 price target on shares of Axonics in a research note on Friday, January 12th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $70.73.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.